Immune microenvironment features and efficacy of <scp>PD‐1/PD‐L1</scp> blockade in non‐small cell lung cancer patients with <scp><i>EGFR</i></scp> or <scp><i>HER2</i></scp> exon 20 insertions

Abstract

NSCLC patients with EGFR/HER2 Ex20ins had similar genomic characteristics and distinct immune features. Patients with EGFR Ex20ins had significantly higher PD-L1 expression than those with HER2 mutations, which may be the potential reason for the different responses to PD-1/PD-L1 blockage.